drug-resistant tuberculosis and group 5 anti-tuberculosis drugs

Authors

shervin shokouhi department of infectious diseases and tropical medicine, shahid beheshti university of medical sciences, tehran, ir iran; department of infectious diseases and tropical medicine, shahid beheshti university of medical sciences, tehran, ir iran. tel: +98-9141491958, fax: +98 21 55416170سازمان اصلی تایید شده: دانشگاه علوم پزشکی شهید بهشتی (shahid beheshti university of medical sciences)

ilad alavi darazam department of infectious diseases and tropical medicine, shahid beheshti university of medical sciences, tehran, ir iran; alimoradian hospital, hamadan university of medical sciences, hamadan, ir iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی شهید بهشتی (shahid beheshti university of medical sciences)

abstract

Sign up for free to access the full text

Already have an account?login

similar resources

Pattern of Adverse Effects of Drugs Used to Treat Multi Drug Resistant Tuberculosis

During treatment of multi drug resistant tuberculosis (MDR-TB), patients suffer from many adverse effects. Severe adverse effects may lead to refusal and discontinuation of treatment. Though national tuberculosis control programs are generally well structured, they do not collect information on adverse effects of drug directly. This study had been designed to observe the pattern of adverse effe...

full text

New drugs and vaccines for drug-resistant Mycobacterium tuberculosis infections.

Tuberculosis remains the most common cause of death due to a single infective organism. Despite the availability of a vaccine and chemotherapeutic options, the global disease burden remains relatively unaffected. The ability of the mycobacterial etiological agents to adopt a semidormant, phenotypically drug-resistant state requires that chemotherapy is both complex and lengthy. The emergence of...

full text

multidrug-resistant and extensively drug-resistant tuberculosis

multidrug-resistant (mdr) and extensively drug-resistant (xdr) tuberculosis (tb) are increasing globally. treatment options for these patients are very limited. although treatment of these patients with standardized regimen is associated with high mortality and morbidity, rational usage of new drugs might be promising. in this study we will review epidemiology of xdr-tb and tdr-tb in iran and t...

full text

Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis.

The continuing spread of drug-resistant tuberculosis (TB) is one of the most urgent and difficult challenges facing global TB control. Patients who are infected with strains resistant to isoniazid and rifampicin, called multidrug-resistant (MDR) TB, are practically incurable by standard first-line treatment. In 2012, there were approximately 450,000 new cases and 170,000 deaths because of MDR-T...

full text

Extensively drug-resistant tuberculosis.

Extensively drug-resistant (XDR) tuberculosis is defined as disease caused by Mycobacterium tuberculosis with resistance to at least isoniazid and rifampicin, any fluoroquinolone, and at least one of three injectable second-line drugs (amikacin, capreomycin, or kanamycin). The definition has applicable clinical value and has allowed for more uniform surveillance in varied international settings...

full text

Drug Resistant Tuberculosis

Drug resistant tuberculosis (DRTB) has hit the tuberculosis control programs like a thunderbolt. It has challenged all the aspects of tuberculosis management, from diagnosis till prognosis. India has had a major contribution in DR TB worldwide, with Mumbai city being the niche for DRTB strains. DRTB has emerged distinctly as a “Creation of mankind” than solely as a “Weapon of God” to curtail th...

full text

My Resources

Save resource for easier access later


Journal title:
archives of pediatric infectious diseases

جلد ۳، شماره ۱ TB، صفحات ۰-۰

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023